Neurocrine Biosciences (NBIX)

[rivervalley]

had an order to short this in the mid 16's but have moved it up a bit :) still moving strong, and not sure where the top will be.

[expediter13]

After hours it was up huge ! Too late to get in and possible short. I am shorting uni-pixel. They are gonna bomb

[TheFinalCD]

it doesn't ...just loved they said [SMART MONEY]

hehe

[TheFinalCD]

we agree, and even expect a possible gap up but then will probably see 14,13,12's

[expediter13]

That is about sells last year. What does that have to do with the price spike and buying ?

[expediter13]

If anyone is good at shorting the afterhours is up 63%. That is a killer short oppurtunity. No way it hold that price...

[bobirw]

Sounds like a short.

[TheFinalCD]

good PII (+) data but still needs to go thru FDA

The data from the study will allow Neurocrine to submit a so-called "End of Phase II" meeting request, as well as finalize the initial draft for Phase III, both of which the company expects to file with the Food and Drug Administration in the first half of this year.

[lady glueck]

thats what we were waiting for. holding some freebies plus accumulated some more in october.
lets see what's up next here. AM trading looks nice so far

[TheFinalCD]

NBIX (15.50) Neurocrine Biosciences -- How One Could Have Used 'Smart Money' And FactSet To Time The Stock

http://www.forbes.com/sites/kaipetainen/2013/09/10/neurocrine-biosciences-how-one-could-have-used-smart-money-and-factset-to-time-the-stock/?partner=yahootix

[TheFinalCD]

NBIX NEW$$$ http://ih.advfn.com/p.php?pid=nmona&article=60567622

[surf1944]

http://phx.corporate-ir.net/phoenix.zhtml?c=68817&p=irol-news&nyo=0

[Stock_Barber]

Nice move lately! Anyone still here?

[biocqr]

Sizing Up Elagolix - A Blockbuster Drug
By Jason Napodano, CFA

Featured blog post...
http://www.biotechinvestorsnetwork.com/

[surf1944]

4:14PM Neurocrine Biosci announces start of second Phase IIb study of VMAT2 Inhibitor NBI-98854 for treatment Of Tardive Dyskinesia (NBIX) 7.98 +0.11 : Neurocrine Biosciences announced that it has initiated a Phase IIb clinical trial of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The design of this six-week Phase IIb study is a randomized, parallel, double-blind, placebo-controlled, dose titration trial of 90 subjects with moderate to severe tardive dyskinesia and underlying mood disorders, gastrointestinal disorders, and schizophrenia or schizoaffective disorder. Topline data is expected in mid-2013

[surf1944]

Neurocrine Biosciences To Present At Deutsche Bank's 2012 dbAccess BioFEST
Live Audio Webcast Tuesday, December 4, 2012
PR NewswirePress Release: Neurocrine Biosciences, Inc. – Tue, Nov 27, 2012 5:00 PM EST

SAN DIEGO, Nov. 27, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting at Deutsche Bank's 2012 dbAccess BioFEST in Boston.

The live presentation takes place on Tuesday, December 4 at 10:45 a.m. Eastern Time / 7:45 a.m. Pacific Time. The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at [phone] or [e-mail]. Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

[surf1944]

Neurocrine Biosciences' Management Presents at Morgan Stanley Global Healthcare Conference - Transcript

http://seekingalpha.com/article/862811-neurocrine-biosciences-management-presents-at-morgan-stanley-global-healthcare-conference-transcript?source=yahoo

[surf1944]

4) Neurocrine Biosciences Inc. (NBIX)
Sector: Healthcare
Industry: Drug Manufacturers - Major
Market Cap: $489.37M
Beta: 0.35

Neurocrine Biosciences Inc. has a 5-Year Projected Earnings Per Share Growth Rate of 69.00%, a Return on Equity of 40.52%, and a Return on Assets of 19.65%. The short interest was 4.59% as of 06/17/2012. Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, stress-related disorders, pain, tardive dyskinesia, uterine fibroids, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company's products in clinical development include Elagolix, a Phase II drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF2 Peptide Agonist, a Phase II drug for cardiovascular diseases; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids.

http://seekingalpha.com/article/666041-7-highly-profitable-small-caps-set-for-strong-growth?source=yahoo

[surf1944]

Neurocrine Biosciences to Present at the 11th Annual Needham Healthcare Conference
Live Audio Webcast Tuesday, April 3, 2012
PR NewswirePress Release: Neurocrine Biosciences, Inc. – Tue, Mar 27, 2012 4:05 PM EDT

SAN DIEGO, March 27, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX - News) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 11th Annual Needham Healthcare Conference in New York.

The live presentation takes place on Tuesday, April 3 at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time. The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at [phone]. Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, tardive dyskinesia, uterine fibroids, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

[Penny Roger$]

Well, looks like you are off to a good start here :)

[lady glueck]

hehe chase it with a shot of whiskey sounds good.
but I like the cocktails better

[Penny Roger$]

Thanks for the heads up. I skip a lot of second notices these days.. If I am off I chase it with a shot of whiskey.

[lady glueck]

...mid/end of march she´s cummin! 3-31-12 is the date
http://phx.corporate-ir.net/phoenix.zhtml?c=68817&p=irol-newsArticle&ID=1658594&highlight=

[Penny Roger$]

~ $NBIX ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $NBIX ~ Earnings expected on Monday *
This Week In Earnings: Earnings are coming or are already posted! This is what the charts look like! If you play the earnings these posts can be very helpful to you!
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=NBIX&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=NBIX&p=W&b=3&g=0&id=p54550695994



~ Barchart: http://barchart.com/quotes/stocks/NBIX?
~ OTC Markets: http://www.otcmarkets.com/stock/NBIX/company-info
~ Google Finance: http://www.google.com/finance?q=NBIX
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=NBIX#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=NBIX+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=NBIX
Finviz: http://finviz.com/quote.ashx?t=NBIX
~ BusyStock: http://busystock.com/i.php?s=NBIX&v=2
~ CandlestickChart: http://www.candlestickchart.com/cgi/chart.cgi?symbol=NBIX&exchange=US
~ Investorshub Trades: http://ih.advfn.com/p.php?pid=trades&symbol=NBIX
~ Investorshub Board Search: http://investorshub.advfn.com/boards/getboards.aspx?searchstr=NBIX
~ Investorshub PostStream Search: http://investorshub.advfn.com/boards/poststream.aspx?ticker=NBIX
~ Investorshub Goodies Search: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18582&srchyr=2011&SearchStr=NBIX
~ Investorshub Message Search: http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=NBIX
~ MarketWatch: http://www.marketwatch.com/investing/stock/NBIX/profile
~ E-Zone Chart: http://www.windchart.com/ezone/signals/?symbol=NBIX
~ 5-Min Wind: http://www.windchart.com/stockta/analysis?symbol=NBIX
~ 10-Min Wind: http://www.windchart.com/stockta/analysis?symbol=NBIX&size=l&frequency=10&color=g
~ 30-Min Wind: http://www.windchart.com/stockta/analysis?symbol=NBIX&size=l&frequency=30&color=g
~ 60-Min Wind: http://www.windchart.com/stockta/analysis?symbol=NBIX&size=l&frequency=60&color=g


http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

[surf1944]

short position

Total Cash (mrq): 111.63M
Total Cash Per Share (mrq): 2.02
Total Debt (mrq): 0.00
Total Debt/Equity (mrq): N/A
Current Ratio (mrq): 2.81
Book Value Per Share (mrq): 1.05

[maniactrader]

WTF? look at VRUS
surely there is something nbix can offer to larger companies.
this was 70$ stock a few years.

[surf1944]

Insider Buying And A Pending Catalyst Send Neurocrine Bioscience's Shares Higher

http://seekingalpha.com/article/299938-insider-buying-and-a-pending-catalyst-send-neurocrine-bioscience-s-shares-higher?source=yahoo

[mlkrborn]

NBIX $5.78 with milestone payment:
Neurocrine Biosciences Receives Second Milestone Payment Of $20 M Under Abbott Collaboration Agreement
Last update: 10/4/2011 4:05:12 PM

[surf1944]

Neurocrine Biosciences Announces the Start of Phase II Study of Elagolix in Uterine Fibroids
RECEIVES MILESTONE PAYMENT OF $10 MILLION UNDER ABBOTT COLLABORATION AGREEMENT

Press Release Source: Neurocrine Biosciences, Inc. On Tuesday September 13, 2011, 8:30 am

SAN DIEGO, Sept. 13, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX - News) today announced that Abbott has started a Phase II clinical trial to evaluate elagolix, a next-generation Gonadotropin Releasing Hormone (GnRH) Receptor Antagonist, in the treatment of uterine fibroids. The initiation of this trial triggered a $10 million milestone payment from Abbott to the Company.

"We are pleased that our collaboration has reached this important milestone with elagolix now being evaluated in a clinical setting for use in treating uterine fibroids," said Kevin C. Gorman, President and Chief Executive Officer of Neurocrine Biosciences. "This is evidence of the clinical momentum for elagolix which is moving forward in endometriosis and now uterine fibroids. We look forward to a continued successful collaboration with Abbott."

Uterine fibroids are benign tumors that form in the wall of the uterus. They are the most common type of growth found in a woman's pelvis and are most common in women aged 30–50 years. While many women do not have symptoms, depending on the size, location and number, uterine fibroids can cause heavy menstrual bleeding, can put pressure on the bladder and rectum, and can cause pain and nausea. Symptoms can also include miscarriage and infertility. Depending on the symptoms, treatment sometimes requires surgery, including the total removal of the uterus.

[surf1944]

Neurocrine Biosci NBIX MKM Partners Buy $12

[surf1944]

Neurocrine Biosciences' CEO Discusses Q2 2011 Results - Earnings Call Transcript

http://seekingalpha.com/article/283131-neurocrine-biosciences-ceo-discusses-q2-2011-results-earnings-call-transcript?source=yahoo

[surf1944]

Neurocrine Biosciences: Solid Financials, Strong Pipeline

eurocrine Biosciences Inc. (NBIX) is a biopharmaceutical company engaged in research and development of medications addressing metabolic system-related diseases and neurological disorders such as anxiety, depression and insomnia.

The company has a goal of advancing one new clinical candidate into development each other year. Its most active program is a hormone receptor antagonist for issues concerning women's health. The lead candidate is elagolix (NBI-56418) for treating endometriosis. In September 2008, the company announced positive Phase 2b data showing reduced loss in bone mineral density, comparable pain reduction and a relatively low incidence of side-effects. Under FDA guidance, a second study was launched in 2010, yielding similarly positive results. (See company press release on the elagolix presentation it delivered June 16th at the World Congress on Endemetriosis.)

Neurocrine Biosences reported that its global partner, Abbott Labs, will advance elagolix to Phase 3 study for endometriosis in late 2011 following a successful end of Phase 2 in March. The partner deal includes treatment options for uterine fibrosis (set for a separate Phase 2 study) and enlarged prostate for male patients. GSK-561679, a compound developed in collaboration with GlaxoSmithKline (GSK) is undergoing Phase 2 studies for major depressive disorders and Phase 1 studies for anxiety and depression.

NBIX also reported successful Phase 2a trials on medication targeting movement disorders and is also developing a product designed to address congestive heart failure which is currently completing pre-clinical safety and toxicology studies.

Sources: S&P Compustat Company Report, FY2011Q1 NBIX summary.

In addition to a strong pipeline, Neucrone Biosciences has zero debt and holds $121M in cash, something of a rarity for a small-cap biopharmaceutical. While traditional valuation metrics are, of course, stratospheric, the company has swung into consistent profitability, showing 3 positive quarters. Long-term, NBIX stands to gain up to $500M in milestones royalties from its established licensing contract on elagolix with Abbott Laboratories (ABT) while the latter assumes all commercialization and development.

Sources: Yahoo! Finance, FY2011Q1 NBIX Earnings Call

Analysts are mostly bullish on the stock, with Piper Jaffray maintaining an overweight recommendation and Standard & Poor's upgrading it to 4/5 stars as of 06.21. Mean 12-month price target is $12.30, implying a 64% upside potential.

The technicals are murky, with the stock trading near 50 and 200-day SMAs:

A sharply defined range between $6.50 and $8.50 has emerged in October of 2010 and has continued through recent tops. As with most biotech equities, the beta is very large.

On the basis of its solid financials, strong pipeline and strategic partnerships with well-established companies like Abbott Labs and GlaxoSmithKline, Nurocrine Biosciences is a BUY for intermediate and long-term investors. Revenue from elagolix are estimated to peak in excess of $1B by 2014, implying a $200M yearly revenue stream for the company and sustain potential for stock price appreciation, while the rest of the pipeline looks very appealing.

Traders looking to establish positions should look for the bottom of the currently defined range and expand exposure in small tranches, to ensure cost averaging.

A conservative option strategy to consider would be selling November 19th $7 puts for an estimated $.65 per contract. If the puts are exercised, the effective per-share price works out to $6.35, below the bottom of established price range. If the puts expire, they would return an annualized rate of about $22% (for comparison purposes only.)

Disclosure: I have no positions in any stocks mentioned, but may initiate a long position in NBIX over the next 72 hours.

http://seekingalpha.com/article/276192-neurocrine-biosciences-solid-financials-strong-pipeline?source=yahoo

[surf1944]

Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor
VMAT2 PRE-INVESTIGATIONAL NEW DRUG APPLICATION MEETING WITH FDA COMPLETED

Press Release Source: Neurocrine Biosciences, Inc. On Thursday June 23, 2011, 8:30 am

SAN DIEGO, June 23, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX - News) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's proprietary Vesicular Monoamine Transporter 2 inhibitor (VMAT2), NBI-98854. The Notice of Allowance indicates that a composition of matter patent on NBI-98854 will have an initial patent term extending to May 2029.

Additionally, on June 17, 2011, the Company held a Pre-Investigational New Drug Application (Pre-IND) meeting with the United States Food and Drug Administration (FDA) Division of Psychiatry Products. As a result of this positive meeting, the Company will submit the final Investigational New Drug Application to the FDA in mid July 2011, followed by the initiation of a second Phase II trial of NBI-98854 in tardive dyskinesia patients later in the third quarter of 2011. The Company has also initiated three-month pre-clinical toxicology studies of NBI-98854 to permit longer duration of treatment in patients.

"We are very pleased with both the patent office decision and the successful pre-IND meeting with the FDA," said Kevin C. Gorman, Chief Executive Officer of Neurocrine Biosciences. "The composition of matter patent will provide us with the maximum commercial timeframe of up to fourteen years for NBI-98854, and the successful FDA meeting confirmed that FDA is very interested in a safe and effective therapy for tardive dyskinesia."

About NBI-98854

VMAT2 is a protein concentrated in the human brain that is primarily responsible for re-packaging and transporting monoamines (dopamine, norepinephrine, serotonin, and histamine) among nerve cells. NBI-98854, developed in the Neurocrine laboratories, is a novel, highly-selective VMAT2 inhibitor that modulates dopamine release during nerve communication, while at the same time having minimal impact on the other monoamines thereby reducing the likelihood of "off target" side effects.NBI-98854 is designed to provide low, sustained, plasma and brain concentrations of active drug to minimize side effects associated with excessive dopamine depletion.

NBI-98854 may be useful in other disorders such as Huntington's chorea, schizophrenia, Tourette's syndrome, and tardive dystonia.

[surf1944]

8:33AM Neurocrine Biosci announced that the USPTO has issued a Notice of Allowance for its proprietary Vesicular Monoamine Transporter 2 inhibitor (NBIX) 7.21 : The Notice of Allowance indicates that a composition of matter patent on NBI-98854 will have an initial patent term extending to May 2029.

[surf1944]

Neurocrine Biosciences, Inc. CEO Discusses Q1 2011 Results - Earnings Call Transcript

http://seekingalpha.com/article/267713-neurocrine-biosciences-inc-ceo-discusses-q1-2011-results-earnings-call-transcript?source=yahoo

[mlkrborn]

NBIX $7.92 now ; research objective ..

Neurocrine Tardive drug meets midstage study goals
Neurocrine Biosciences' drug for Tardive Dyskinesia meets midstage study goals.
v
Related Quotes
Symbol Price Change
NBIX 7.90 +0.67
Chart for Neurocrine Biosciences, Inc.
{"s" : "nbix","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""}
On Tuesday April 5, 2011, 10:11 am

SAN DIEGO (AP) -- Neurocrine Biosciences Inc. said Tuesday that its potential Tardive Dyskinesia treatment met key safety and effectiveness goals in a midstage study and the company will continue developing the drug.

Tardive Dyskinesia's symptoms include involuntary, repetitive movements of the extremities, lip smacking, grimacing, tongue protrusion, and rapid eye movements. There is currently no treatment for the condition.

The study, conducted in Canada, involved 10 patients with schizophrenia and moderate to severe Tardive Dyskinesia. Over the 12 days of treatment, the company said NBI-98854 was generally well tolerated and patients showed a "marked improvement" in abnormal movements.

NBI-98854 is an inhibitor of the VMAT2 protein, which is concentrated in the human brain and is mainly responsible for re-packaging and transporting hormones such as dopamine and serotonin among nerve cells. NBI-98854 is designed to modulate the release of dopamine during nerve communication without major side effects.

A Phase II study will be launched in the U.S. in the third quarter, and a larger, longer-term Phase IIb study will be started early next year to assess three-month dosing of NBI-98854.

Shares of Neurocrine rose 50 cents, or 6.9 percent, to $7.73 in morning trading. The stock has traded between $2.30 and $9.30 over the last 52 weeks.

Follow Yahoo! Finance on Twitter; become a fan on Facebook.

[Keith43042]

Two more weeks to go...............

[surf1944]

4:06PM Neurocrine Biosci announces top-line results of corticotropin releasing factor antagonist GSK561679 for treatment of major depressive disorder; Study did not demonstrate a treatment effect compared to placebo (NBIX) 6.25 +0.18 : Co announced top-line efficacy and safety results from a Phase II clinical trial utilizing Corticotropin Releasing Factor (CRF1) receptor antagonist GSK561679 in patients currently experiencing a major depressive episode. This double-blind, placebo controlled trial randomized 150 patients into two treatment arms, 350 mg of GSK561679 daily and placebo, and was conducted in the United States by GlaxoSmithKline (GSK) under the GSK/Neurocrine CRF1 collaboration. The primary endpoint was change from baseline in the Bech Melancholia scale at Week 6 and a key secondary endpoint was change from baseline in the HAMD-17 scale at Week 6. Results of statistical analysis using the intent-to-treat population revealed no benefit of GSK561679 compared with placebo on both the Bech Melancholia and HAMD-17 endpoints. The top-line results are based on the six week placebo-controlled portion of the study for the intent to treat population of 145 patients. From a safety perspective, there were no significant adverse events, and the drug was generally well tolerated. Three separate academic collaborative clinical trials are ongoing to evaluate the effects of GSK561679 in Post Traumatic Stress Disorder, anxiety and alcoholism.

[surf1944]

Neurocrine Biosciences to Present at Two Upcoming Conferences on September 16 and September 22

http://finance.yahoo.com/news/Neurocrine-Biosciences-to-prnews-2960831149.html?x=0&.v=1

[surf1944]

Neurocrine Biosciences, Inc. Q2 2010 Earnings Call Transcript

http://seekingalpha.com/article/217339-neurocrine-biosciences-inc-q2-2010-earnings-call-transcript

[mlkrborn]

NBIX 6.45 now.. patience rewarding!

[Kylegirl]

Great video on Endometriosis.

[MONEYMADE]

,,,,,,,,I don't know what Endometriosis is? But I think I just got it!!!!!

[surf1944]

6:15AM Neurocrine Biosciences and Abbott Labs announce global agreement to develop and commercialize elagolix for treatment of endometriosis (NBIX) 4.70 : Abbott (ABT) and Neurocrine Biosciences announce that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids. Under the terms of the agreement, Abbott will receive worldwide exclusive rights to develop and commercialize elagolix and all next-generation GnRH antagonists for women's and men's health. Abbott will make an upfront payment of $75 mln and will fund all ongoing development activities. Neurocrine is eligible to receive additional milestone payments of approx $500 mln from Abbott for the achievement of certain development, regulatory and commercial milestones; funding for certain internal collaboration expenses; plus royalty payments on any future product sales. NBIX will host a conf. call at 08:45 EST to discuss the agreement with ABT.

[newmillionaire]

NBIX Highlighted In Trading Synopsis

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is one of the few companies that can be proud of the positive movement of its shares in today's sluggish market.

Read More...

[surf1944]

Neurocrine Biosciences Announces Positive Results in Daisy PETAL Study

http://finance.yahoo.com/news/Neurocrine-Biosciences-prnews-3475954244.html?x=0&.v=1

[surf1944]

Neurocrine Biosciences to Present at the Deutsche Bank 35th Annual Health Care Conference
Live Audio Webcast Monday, May 3, 2010

Press Release Source: Neurocrine Biosciences, Inc. On Monday April 26, 2010, 1:00 pm
SAN DIEGO, April 26 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq:NBIX - News) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Deutsche Bank 35th Annual Health Care Conference in Boston.

The live presentation takes place Monday, May 3, 2010 at 10:00 a.m. Eastern Time / 7:00 a.m. Pacific Time. The presentation will be simultaneously webcast and may be accessed on the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at [phone]. Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

[hptaxis]

Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
http://www.prnewswire.com/news-releases/neurocrine-biosciences-inc-announces-exercise-of-over-allotment-option-for-common-stock-offering-87856587.html

SAN DIEGO, March 16 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the underwriter of its recently completed public offering of common stock has exercised in full its option to purchase an additional 1,365,000 shares of common stock to cover over-allotments. The sale of the additional shares closed on March 16, 2010. When taking into account the sale of the additional shares at a price to the public of $2.20 per share, the aggregate gross proceeds from both closings of the offering, before underwriting discounts and commissions and other offering expenses, were approximately $23 million.

[surf1944]

Neurocrine Biosci NBIX Piper Jaffray Neutral

[surf1944]

Neurocrine Biosciences Inc. Q4 2009 Earnings Call Transcript

http://seekingalpha.com/article/186492-neurocrine-biosciences-inc-q4-2009-earnings-call-transcript?source=yahoo